How does ARA-290 map to the hallmarks of aging?

ARA-290's longevity relevance maps to specific hallmarks based on its mechanism. Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue. Reduces inflammatory cytokine release and supports nerve and tissue repair. Critically, it does not bind the homodimeric EPOR responsible for erythropoiesis. For users tracking healthspan-relevant biomarkers across cycles, the relevant endpoints are determined by which hallmark the compound primarily targets — telomere maintenance, senescence modulation, mitochondrial biogenesis, autophagy induction, inflammaging, or epigenetic clock effects. The framework above identifies the dominant contribution.

What is the mechanism of action of ARA-290?

Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue. Reduces inflammatory cytokine release and supports nerve and tissue repair. Critically, it does not bind the homodimeric EPOR responsible for erythropoiesis. For healthspan and biological-age applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue. The longevity / hallmarks of aging interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What are the safety considerations for ARA-290?

Excellent tolerability in published trials. Does not raise hemoglobin. Watch for rare injection site reactions. For healthspan and biological-age use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. ARA-290's ~2 min plasma; long tissue effect pharmacokinetic profile and subq administration route influence the side-effect profile in predictable ways.

How should ARA-290 be stored and reconstituted?

Lyophilised ARA-290 stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

Home/ Compounds/ ARA-290

ARA-290

Longevity

Healthspan-relevant evaluation of ARA-290 starts with mapping its mechanism to the hallmarks of aging and asking which of the nine hallmarks its primary pharmacology engages. Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue Reduces inflammatory cytokine release and supports nerve and tissue repair. Critically, it does not bind the homodimeric EPOR responsible for erythropoiesis.. The ~2 min plasma; long tissue effect pharmacokinetic profile, the cycle-based 4 mg 1x daily subq dosing pattern, and the longevity-specific stack partners on adjacent hallmarks together produce the framework documented below.

Longevity / Hallmarks of Aging Applications

NAD+ MetabolismTelomere SupportGenomic StabilityInflammagingHallmarks of Aging

Key Takeaways

Longevity lens: ARA-290 maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers.
Mechanism: Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue.
Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles.
Longevity protocol: cycle-based 4 mg 1x daily subq dosing; 8-12 week cycles favoured over continuous administration.
Longevity stack partners: Epithalon, Thymalin, NAD+.

Longevity / Hallmarks of Aging Mechanism

For longevity-relevant evaluation, ARA-290's mechanism is examined against the hallmarks of aging rather than against acute clinical endpoints. Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue. Reduces inflammatory cytokine release and supports nerve and tissue repair. Critically, it does not bind the homodimeric EPOR responsible for erythropoiesis. The subsections below address the hallmarks mapping, cellular reprogramming layer, healthspan markers, and dosing-pattern conventions in longevity research.

Mapping to the hallmarks of aging

ARA-290's longevity relevance is best evaluated by mapping its mechanism to the hallmarks-of-aging framework. Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue. Reduces inflammatory cytokine release and supports nerve and tissue repair. Critically, it does not bind the homodimeric EPOR responsible for erythropoiesis. This places its dominant contribution in the integrative hallmarks (systemic and inflammatory) layer of the framework, with secondary effects on adjacent hallmarks that combine to produce the broader healthspan-relevant phenotype.

Healthspan markers and biological age

For users measuring epigenetic age, telomere length, or composite biological-age markers (Horvath, PhenoAge, GrimAge) before and after ARA-290 cycles, the question is whether the intervention measurably moves these markers. Current evidence varies by compound but the framework for evaluation is shared: paired pre-post measurement with appropriate inter-test interval.

Cellular reprogramming and gene expression

Where ARA-290 has measurable effects on transcriptional programmes, the direction of effect tends to be toward younger phenotypes rather than away from them. This signature — partial reversal of age-associated expression changes — is what distinguishes a true longevity-relevant compound from a symptomatic one. The signal strength varies, but the direction is what longevity researchers track.

Longevity / Hallmarks of Aging Applications

Hallmarks of Aging

For hallmarks of aging as a longevity-relevant endpoint, ARA-290 is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Inflammaging

Inflammaging maps to one of the hallmarks of aging and is one of the dimensions on which ARA-290 is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Mitochondrial Biogenesis

ARA-290's contribution to mitochondrial biogenesis as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

mTOR Modulation

For mtor modulation as a longevity-relevant endpoint, ARA-290 is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	4 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	2 mg	4–6 weeks initial cycle
Longevity focus	SubQ	4 mg	1x daily SubQ
Maintenance phase	SubQ	3 mg	Ongoing with periodic pauses

Dose timing for ARA-290 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

ARA-290 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.

ARA-290 + Epithalon: Identified by Khavinson in St. Pairs naturally with ARA-290's mechanism in longevity / hallmarks of aging protocols.
ARA-290 + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with ARA-290's mechanism in longevity / hallmarks of aging protocols.
ARA-290 + NAD+: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Pairs naturally with ARA-290's mechanism in longevity / hallmarks of aging protocols.
ARA-290 + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with ARA-290's mechanism in longevity / hallmarks of aging protocols.

Safety & Regulatory Status

WADA: Not specifically listed (EPO analogues require care) FDA: Unapproved (Phase II/III in sarcoidosis & neuropathy) Research: Multiple Phase II human trials

Excellent tolerability in published trials. Does not raise hemoglobin. Watch for rare injection site reactions.

Lens-specific safety considerations for longevity / hallmarks of aging use of ARA-290: Excellent tolerability in published trials. Does not raise hemoglobin. Watch for rare injection site reactions. Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss

PMID 30760272

Supporting

Cibinetide (ARA 290) in diabetic neuropathy

PMID 27659024

ARA-290 vs Related Peptides

Compound	Profile	Onset	Best For
ARA-290	EPO-derived tissue-protective peptide	~2 min plasma; long tissue effect	Longevity
Epithalon	Pineal-derived tetrapeptide	Very short (minutes)	A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies
Thymalin	Thymic polypeptide extract	Variable	A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease
MOTS-c	Mitochondrially-encoded peptide	Hours; tissue-distributed	A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

How do I know if ARA-290 is working?

Track outcome metrics that match the compound's primary mechanism: epigenetic age (DNA methylation panels), inflammatory markers (hsCRP, IL-6), metabolic flexibility (HbA1c, fasting insulin, HOMA-IR), body composition (DEXA), and subjective markers (sleep depth, recovery, well-being). Paired pre-post measurement around cycles is the standard framework.

What are the long-term safety considerations?

Long-term safety data for most peptide compounds is limited to a small number of well-studied molecules with multi-decade clinical observation. For most others, the long-term framework relies on mechanism-based risk assessment plus accumulating clinical experience. Cycle-based dosing and periodic re-evaluation are appropriate for compounds without 10+ year human safety data.

Does ARA-290 interact with rapamycin, metformin, or other longevity stacks?

Most peptide compounds are compatible with the standard longevity small-molecule stack (rapamycin, metformin, NAD precursors, senolytics in pulsed protocols). Interactions where present are typically additive rather than competitive. Verify case-specifically with a longevity-informed clinician.

Does ARA-290 actually extend lifespan?

Direct lifespan extension in humans cannot be inferred from current data for any peptide compound. The relevant question is whether ARA-290 measurably moves healthspan-relevant biomarkers — epigenetic age, telomere length, inflammatory panels, metabolic flexibility — in the direction of younger phenotypes. Some compounds in this class have measurable effects on these markers; the lifespan extrapolation remains inferential.

How does ARA-290's half-life affect dosing?

ARA-290 has a plasma half-life of ~2 min plasma; long tissue effect, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 1x daily subq dosing at 4 mg per dose explains the typical onset timeline for healthspan and biological-age endpoints.

Should I cycle ARA-290?

Standard cycle for ARA-290 is 8–12 weeks of 1x daily subq 4 mg dosing via subq, followed by a 4 week complete off-period. The off-period is calibrated to ARA-290's ~2 min plasma; long tissue effect half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

Clinical Protocol

Start a ARA-290 Protocol

Alukard provides physician-supervised longevity protocols with GMP-certified ARA-290 and GMP-certified compounds with biological age testing and healthspan markers.

Get Protocol

Quick Facts

Molecular weight: 1257 Da
Sequence length: 11 aa
Half-life: ~2 min plasma; long tissue effect
WADA: Not specifically listed (EPO analogues require care)
FDA: Unapproved (Phase II/III in sarcoidosis & neuropathy)
Research: Multiple Phase II human trials

Stack Partners

Epithalon

Thymalin

NAD+

MOTS-c

GHK-Cu

Research Note

All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for ARA-290 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised longevity protocols

Start Your Longevity / Hallmarks of Aging Protocol for ARA-290

Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised